Evidence map›Paper›PMID 41669830›Full record

ArticleStroke2026

Design Matters: How Methodological Decisions May Have Shaped the Findings of CREST-2.

Marc I Chimowitz

Abstract read
In one paragraph

Article in Stroke, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. CREST-2 findings are unchanged using an aggregated control group for the CAS and CEA trial.Postepy w kardiologii interwencyjnej = Advances in interventional cardiology · 2026
    Article
  2. Article
  3. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

1 author.

Marc I ChimowitzDepartment of Neurology, Medical University of South Carolina, Charleston (M.I.C.).ORCID 0000-0001-5437-9245

Funding

CREST-2 Clinical Coordinating CenterU01NS080168 · NINDS · MAYO CLINIC JACKSONVILLE · PI Thomas G Brott, JAMES F MESCHIA · 2014 to 2026
$56.3M
Comparison of Anti-coagulation and anti-Platelet Therapies for Intracranial Vascular AtherostenosisU01NS117450 · NINDS · UNIVERSITY OF FLORIDA · PI MARC IVOR CHIMOWITZ, Brian Lim Hoh · 2021 to 2026
$29.6M
NINDS NIH HHS U01 NS080168NINDS NIH HHS U01 NS117450
6 · The paper itself

Abstract

CREST-2 (Carotid Revascularization and Medical Management for Asymptomatic Carotid Stenosis Trials) comprised 2 parallel randomized trials in asymptomatic carotid stenosis comparing medical management alone with medical management plus carotid artery stenting or carotid endarterectomy. Carotid stenting achieved a modest but statistically significant 4-year reduction in primary events, whereas carotid endarterectomy did not. This commentary examines methodological features that may have favored the revascularization arms, including omission of peri-procedural myocardial infarction and major hemorrhage as end points; allowing operator-team members to perform neurological assessments; highly selective credentialing of carotid stenting operators; and a primary analysis that weighted early and late events equally. Taken together, these methodological features and ongoing advances in contemporary medical therapy suggest that carotid stenting, carotid endarterectomy, and medical management may yield similar outcomes in clinical practice.

Indexed as

Carotid StenosisEndarterectomy, CarotidRandomized Controlled Trials as TopicResearch DesignStentsHumansMyocardial InfarctionStrokecarotid stenosiscredentialingendarterectomymyocardial infarctionrisk factorsstentsstroke

Identifiers

PMID41669830
PMCPMC12916033

What Socratic holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.